Akero Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy AKRO

*Your capital is at risk

$54.65

+0 (+0%)

At Close: Mar 06, 2026

Akero Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -98.69. In total, the insiders bought 319.39K and sold 4.79M AKRO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-98.69
● Buy	319.39K shares
● Sell	4.79M shares
15% Buy Activity Negligible or No Correlation
Sell Signal High Confidence Dec 09, 2025 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -98.69. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (15% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Henderson Jane Director	Director	13 000 Value: $327.6K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Young Jonathan Chief Operating Officer	C-Suite Officer	70 279 Value: $2.05M
Dec 09, 2025 Sell	Common Stock D-Return	Young Jonathan Chief Operating Officer	C-Suite Officer	47 573 Value: $0
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Henderson Jane Director	Director	11 797 Value: $82.7K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Young Jonathan Chief Operating Officer	C-Suite Officer	74 053 Value: $2.10M
Dec 09, 2025 Sell	Common Stock D-Return	Heyman Tomas J. Director	Director	9 398 Value: $0
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Heyman Tomas J. Director	Director	26 000 Value: $598.5K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Heyman Tomas J. Director	Director	15 000 Value: $762.5K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Heyman Tomas J. Director	Director	15 000 Value: $122.0K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Heyman Tomas J. Director	Director	13 000 Value: $342.2K
Dec 09, 2025 Sell	Common Stock D-Return	Xu Yuan Director	Director	9 398 Value: $0
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Cheng Andrew President And CEO	CEO / President	10 000 Value: $160.0K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Harrison Seth Loring Director	Director	15 000 Value: $762.5K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Harrison Seth Loring Director	Director	15 000 Value: $122.0K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Harrison Seth Loring Director	Director	13 000 Value: $342.2K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Harrison Seth Loring Director	Director	13 000 Value: $327.6K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Harrison Seth Loring Director	Director	26 000 Value: $519.2K
Dec 09, 2025 Sell	Common Stock D-Return	Harrison Seth Loring Director	Director	9 398 Value: $0
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Harrison Seth Loring Director	Director	26 000 Value: $598.5K
Dec 09, 2025 Sell	Common Stock D-Return	Graham G. Walmsley Director	Director	9 398 Value: $0
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Graham G. Walmsley Director	Director	15 000 Value: $762.5K
Dec 09, 2025 Sell	Common Stock D-Return	Judy Chou Director	Director	9 398 Value: $0
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Judy Chou Director	Director	26 000 Value: $598.5K
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Rolph Timothy Chief Scientific Officer	Officer	56 579 Value: $1.65M
Dec 09, 2025 Sell	Stock Option (Right to Buy) D-Return	Rolph Timothy Chief Scientific Officer	Officer	119 969 Value: $2.38M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AKERO THERAPEUTICS INC.

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a ...

Read Full Profile Here